Background
Patients and methods
Patient selection
Stability assessment
Treatment
Characteristics | Value | Percent |
---|---|---|
Age (years) | ||
Median | 75.3 | – |
Range | 70.1–88.4 | – |
Gender (n) | ||
Female | 141 | 43.8 |
Male | 181 | 56.2 |
Karnofsky PS (%) | ||
90 | 18 | 5.6 |
80 | 82 | 25.5 |
70 | 115 | 35.7 |
60 | 78 | 24.2 |
50 | 21 | 6.5 |
40 | 7 | 2.2 |
30 | 1 | 0.3 |
Number of spinal bone metastases (n) | ||
Median | 2 | – |
Range | 1–13 | – |
Solitary | 140 | 43.5 |
Multiple | 182 | 56.5 |
Spine involvement (n) | ||
Thoracic | 199 | 61.8 |
Lumbar | 123 | 38.2 |
Primary tumor (n) | ||
Breast carcinoma | 47 | 14.6 |
NSCLC | 117 | 36.3 |
SCLC | 11 | 3.4 |
Renal carcinoma | 53 | 16.5 |
Colorectal cancer | 33 | 10.2 |
Prostate cancer | 13 | 4.0 |
Urothelium carcinoma | 21 | 6.5 |
HCC | 2 | 0.6 |
ACC (head and neck) | 2 | 0.6 |
HNSCC | 3 | 0.9 |
Vulvar carcinoma | 2 | 0.6 |
Ovarian cancer | 2 | 0.6 |
Uterine cancer | 2 | 0.6 |
Malignant melanoma | 14 | 4.3 |
Distant extraskeletal metastases (n) | 120 | 37.3 |
Brain | 30 | 9.3 |
Lung | 67 | 20.8 |
Liver | 63 | 19.6 |
Skin | 18 | 5.6 |
Single radiation dose (Gy) | ||
Median | 3 | – |
Range | 2–4 | – |
Cumulative dose (Gy) | ||
Median | 30 | – |
Range | 8–40 | – |
Fractionation of RT (n) | ||
1 × 8 Gy | 1 | 0.3 |
5 × 4 Gy | 3 | 0.9 |
10 × 2 Gy | 3 | 0.9 |
10 × 3 Gy | 230 | 71.4 |
12 × 3 Gy | 1 | 0.3 |
14 × 2.5 Gy | 27 | 8.4 |
20 × 2 Gy | 57 | 17.7 |
Indications for RT (n) | ||
Pain | 272 | 84.5 |
Instability | 209 | 64.9 |
Neurologic deficit | 8 | 2.5 |
Chemotherapy (n) | 144 | 44.7 |
Other treatments for bone metastases (n) | ||
Orthopedic corset | 149 | 46.3 |
Bisphosphonates | 186 | 57.8 |
Statistical analysis
Results
Stability analysis
Subtypes at follow-up 1 | |||||||||
---|---|---|---|---|---|---|---|---|---|
A | B | C | D | E | F | G | Total | ||
Subtypes before RT | A | 24 | 1 | 0 | 0 | 0 | 0 | 0 | 25 |
B | 3 | 23 | 2 | 0 | 0 | 0 | 0 | 28 | |
C | 0 | 2 | 34 | 1 | 0 | 0 | 0 | 37 | |
D | 2 | 1 | 6 | 18 | 0 | 0 | 0 | 27 | |
E | 3 | 0 | 4 | 1 | 42 | 2 | 0 | 52 | |
F | 0 | 1 | 4 | 1 | 1 | 27 | 0 | 34 | |
G | 2 | 0 | 0 | 0 | 0 | 2 | 1 | 5 | |
Total | 34 | 28 | 50 | 21 | 43 | 31 | 1 | 208 |
Subtypes at follow-up 2 | |||||||||
---|---|---|---|---|---|---|---|---|---|
A | B | C | D | E | F | G | Total | ||
Subtypes before RT | A | 18 | 1 | 0 | 0 | 0 | 0 | 0 | 19 |
B | 5 | 17 | 2 | 0 | 0 | 0 | 0 | 24 | |
C | 4 | 5 | 22 | 1 | 0 | 0 | 0 | 32 | |
D | 6 | 0 | 7 | 7 | 0 | 0 | 0 | 20 | |
E | 4 | 2 | 5 | 0 | 19 | 2 | 0 | 32 | |
F | 0 | 1 | 4 | 0 | 0 | 16 | 0 | 21 | |
G | 2 | 0 | 0 | 0 | 0 | 2 | 1 | 5 | |
Total | 39 | 26 | 40 | 8 | 19 | 20 | 1 | 152 |
Tumor entity | Stabilization rate at FU1 | Stabilization rate at FU2 |
---|---|---|
Breast cancer | 27% (8/30) | 53% (10/19) |
Lung cancer | 21% (12/57) | 42% (16/38) |
NSCLC | 23% (12/53) | 42% (16/38) |
SCLC | 0% (0/4) | NA |
Renal cancer | 22% (2/9) | 29% (2/7) |
Colorectal cancer | 14% (1/7) | 40% (2/5) |
HCC | 0% (0/2) | 0% (0/1) |
HNSCC | 0% (0/1) | NA |
ACC | 0% (0/1) | NA |
Malignant melanoma | 0% (0/2) | 0% (0/2) |
Uterine cancer | 0% (0/1) | 100% (1/1) |
Vulvar cancer | 0% (0/1) | NA |
Prostate cancer | 0% (0/2) | 0% (0/1) |
Urothelial cancer | 0% (0/5) | 0% (0/4) |
1st follow-up | 2nd follow-up | |||||
---|---|---|---|---|---|---|
Predictor | p-value | OR | CI | p-value | OR | CI |
Age | 0.243 | 1.05 | 0.968–1.140 | 0.224 | 1.05 | 0.970–1.140 |
Poorly represented cancersa (vs. breast cancer) | 0.016 | 4.29 | 1.309–14.090 | 0.021 | 3.47 | 1.209–9.970 |
Colorectal cancer (vs. breast cancer) | 0.388 | 1.92 | 0.435–8.520 | 0.815 | 0.86 | 0.244–3.030 |
Renal cancer (vs. breast cancer) | 0.476 | 1.69 | 0.398–7.210 | 0.167 | 2.90 | 0.640–13.130 |
Lung cancer (vs. breast cancer) | 0.048 | 2.33 | 1.009–5.370 | 0.029 | 2.48 | 1.096–5.630 |
KPS (<70% vs. ≥70%) | 0.551 | 1.01 | 0.977–1.040 | 0.464 | 0.99 | 0.956–1.020 |
Chemotherapy (yes vs. no) | 0.723 | 1.13 | 0.567–2.270 | 0.821 | 0.93 | 0.483–1.780 |
Location (thoracic vs. lumbar spine) | 0.526 | 1.26 | 0.613–2.600 | 0.829 | 1.08 | 0.555–2.080 |
Number of SBM (1 vs. >1) | 0.906 | 1.01 | 0.880–1.160 | 0.426 | 1.06 | 0.921–1.210 |
Extraskeletal metastases (yes vs. no) | 0.206 | 1.67 | 0.755–3.700 | 0.648 | 1.18 | 0.582–2.390 |
Bisphosphonates (yes vs. no) | 0.662 | 1.18 | 0.556–2.520 | 0.182 | 1.63 | 0.797–3.310 |
Fractures before RT (yes vs. no) | 0.037 | 2.81 | 1.066–7.40 | 0.026 | 2.72 | 1.127–6.58 |
Survival analysis
Univariate testing | Multivariate testing | |||||
---|---|---|---|---|---|---|
Predictor | p-value | HR | CI | p-value | HR | CI |
Age | 0.197 | 1.017 | 0.991–1.043 | 0.507 | 1.009 | 0.982–1.038 |
Poorly represented cancersa (vs. breast cancer) | 0.029 | 1.529 | 1.044–2.240 | 0.016 | 1.663 | 1.103–2.509 |
Colorectal cancer (vs. breast cancer) | 0.007 | 1.858 | 1.188–2.907 | NA | 1.548 | 0.879–2.725 |
Renal cancer (vs. breast cancer) | 0.737 | 1.071 | 0.718–1.598 | NA | 1.116 | 0.665–1.872 |
Lung cancer (vs. breast cancer) | 0.008 | 1.576 | 1.127–2.206 | NA | 1.602 | 1.133–2.265 |
KPS (<70% vs. ≥70%) | <0.001 | 0.954 | 0.944–0.964 | <0.001 | 0.953 | 0.942–0.964 |
Chemotherapy (yes vs. no) | 0.151 | 1.177 | 0.943–1.469 | 0.036 | 1.295 | 1.018–1.647 |
Location (thoracic vs. lumbar spine) | 0.523 | 1.077 | 0.858–1.351 | 0.664 | 1.054 | 0.832–1.335 |
Number of SBM (1 vs. >1) | 0.004 | 1.066 | 1.021–1.112 | 0.031 | 1.055 | 1.006–1.107 |
Extraskeletal metastases (yes vs. no) | 0.276 | 1.134 | 0.904–1.423 | 0.711 | 0.953 | 0.740–1.228 |
Bisphosphonates (yes vs. no) | 0.381 | 0.905 | 0.724–1.131 | 0.295 | 0.834 | 0.596–1.167 |
Fractures before RT (yes vs. no) | 0.098 | 1.258 | 0.958–1.651 | 0.383 | 1.138 | 0.853–1.518 |